FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109090088> ?p ?o ?g. }

• W2109090088 endingPage "1191" @default.
• W2109090088 startingPage "1186" @default.
• W2109090088 abstract "No AccessJournal of UrologyAdult Urology1 Oct 2012Cyclosporine A for Refractory Interstitial Cystitis/Bladder Pain Syndrome: Experience of 3 Tertiary Centers John B. Forrest, Christopher K. Payne, and Deborah R. Erickson John B. ForrestJohn B. Forrest Urologic Specialists of Oklahoma, Inc., Tulsa, Oklahoma More articles by this author , Christopher K. PayneChristopher K. Payne Department of Urology, Stanford University, Stanford, California Financial interest and/or other relationship with Allergan, Astellas and Medtronic. More articles by this author , and Deborah R. EricksonDeborah R. Erickson Department of Surgery, Division of Urology, University of Kentucky College of Medicine, Lexington, Kentucky Financial interest and/or other relationship with Trillium Therapeutics. More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.06.023AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Cyclosporine A is a fifth-tier treatment option in the American Urological Association guidelines for interstitial cystitis/bladder pain syndrome. It was more effective than pentosanpolysulfate in a Finnish trial, but experience elsewhere is limited. Some centers use cyclosporine A off label for carefully selected patients but the number of patients in each center is small. We performed a retrospective review combining data from 3 tertiary centers that focus on interstitial cystitis/bladder pain syndrome. Materials and Methods: Charts were reviewed for patients with interstitial cystitis/bladder pain syndrome who received cyclosporine A. Response was defined as markedly improved on the 7-point global response assessment (2 centers) or as at least a 50% decrease in Interstitial Cystitis Symptom Index score (1 center). Results: The study included 14 men and 30 women. Mean patient age was 55.5 years (range 27 to 75) and mean followup was 20.8 months (range 3 to 81). A total of 34 patients had Hunner lesions. Of these patients 29 (85%) responded but 6 eventually stopped cyclosporine A for adverse events, resulting in a success rate of 68% (23 of 34) for patients with Hunner lesions. In contrast, only 3 of 10 patients without Hunner lesions responded (30%). For all responders, the response occurred within 4 months. Conclusions: Cyclosporine A had a high success rate for patients with Hunner lesions in whom more conservative options, including endoscopic treatment, had failed. The success rate was low for patients without Hunner lesions. A 3 to 4-month trial is sufficient time to assess response. Adverse events were common and led to discontinuation of cyclosporine A for some patients. Close monitoring is needed, especially for blood pressure and renal function. References 1 : The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn2002; 21: 167. Google Scholar 2 : Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur Urol2008; 53: 60. Google Scholar 3 : AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol2011; 185: 2162. Link, Google Scholar 4 : Long-term results of reconstructive surgery in patients with bladder pain syndrome/interstitial cystitis: subtyping is imperative. Urology2007; 70: 638. Google Scholar 5 : Interstitial cystitis: early diagnosis, pathology, and treatment. Urology1978; 12: 381. Google Scholar 6 : Chronic interstitial cystitis: a heterogeneous syndrome. J Urol1987; 137: 35. Link, Google Scholar 7 : Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol2008; 179: 1850. Link, Google Scholar 8 : Discovery of morphological subgroups that correlate with severity of symptoms in interstitial cystitis: a proposed biopsy classification system. J Urol2007; 177: 142. Link, Google Scholar 9 : Nitric oxide as an objective marker for evaluation of treatment response in patients with classic interstitial cystitis. J Urol2004; 172: 2261. Link, Google Scholar 10 : Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol2005; 173: 841. Link, Google Scholar 11 : Efficacy and safety of cyclosporine A in patients with refractory systemic lupus erythematosus in a daily clinical practice. Lupus2010; 19: 162. Google Scholar 12 : Behçet's disease: an algorithmic approach to its treatment. Arch Dermatol Res2009; 301: 693. Google Scholar 13 : Current topics in autoimmune hepatitis. Dig Liver Dis2010; 42: 757. Google Scholar 14 : Cyclosporine A in the long-term management of systemic lupus erythematosus. J Biol Regul Homeost Agents2011; 25: 397. Google Scholar 15 : The use of cyclosporine in dermatology: part I. J Am Acad Dermatol2010; 63: 925. Google Scholar 16 : Cyclosporine A or tacrolimus for hepatitis C recurrence?: An old debate. Am J Transplant2011; 11: 1559. Google Scholar 17 : Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol2004; 171: 2138. Link, Google Scholar 18 : Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol2005; 174: 2235. Link, Google Scholar 19 : Interstitial cystitis: a rare manifestation of primary Sjögren's syndrome, successfully treated with low dose cyclosporine. Rheumatol Int2012; 32: 1215. Google Scholar 20 : Evaluation of symptoms in patients with interstitial cystitis treated with cyclosporine A. J Urol2007; 177: 41. abstract 121. Link, Google Scholar 21 : Responsiveness of symptom scales for interstitial cystitis. Urology2006; 67: 55. Google Scholar 22 : Interstitial cystitis and systemic autoimmune diseases. Nat Clin Pract Urol2007; 4: 484. Google Scholar 23 : Intercurrent autoimmune conditions in classic and non-ulcer interstitial cystitis. Scand J Urol Nephrol2003; 37: 60. Google Scholar 24 : Gene expression profile of bladder tissue of patients with ulcerative interstitial cystitis. BMC Genomics2009; 10: 199. Google Scholar 25 : CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol2010; 183: 1206. Link, Google Scholar 26 : Re: cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol2006; 176: 838. Link, Google Scholar 27 : Tacrolimus in the treatment of bladder pain syndrome/interstitial cystitis (BPS/IC): a pilot study. Eur Urol2010; 9: 212. abstract 640. Google Scholar 28 : Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol2011; 185: 901. Link, Google Scholar 29 : Are ulcerative and nonulcerative interstitial cystitis/painful bladder syndrome 2 distinct diseases?: A study of coexisting conditions. Urology2011; 78: 301. Google Scholar 30 : Symptom profile variability of interstitial cystitis/painful bladder syndrome by age. BJU Int2012; 109: 1356. Google Scholar © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetailsCited byClemens J, Erickson D, Varela N and Lai H (2022) Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain SyndromeJournal of Urology, VOL. 208, NO. 1, (34-42), Online publication date: 1-Jul-2022.Bosch P (2018) A Randomized, Double-Blind, Placebo Controlled Trial of Adalimumab for Interstitial Cystitis/Bladder Pain SyndromeJournal of Urology, VOL. 191, NO. 1, (77-82), Online publication date: 1-Jan-2014.Steers W (2018) This Month in Adult UrologyJournal of Urology, VOL. 188, NO. 4, (1061-1062), Online publication date: 1-Oct-2012. Volume 188Issue 4October 2012Page: 1186-1191 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Keywordscyclosporineinterstitialcystitisdrug therapyMetricsAuthor Information John B. Forrest Urologic Specialists of Oklahoma, Inc., Tulsa, Oklahoma More articles by this author Christopher K. Payne Department of Urology, Stanford University, Stanford, California Financial interest and/or other relationship with Allergan, Astellas and Medtronic. More articles by this author Deborah R. Erickson Department of Surgery, Division of Urology, University of Kentucky College of Medicine, Lexington, Kentucky Financial interest and/or other relationship with Trillium Therapeutics. More articles by this author Expand All Advertisement PDF downloadLoading ..." @default.
• W2109090088 created "2016-06-24" @default.
• W2109090088 creator A5033530114 @default.
• W2109090088 creator A5042149312 @default.
• W2109090088 creator A5069976268 @default.
• W2109090088 date "2012-10-01" @default.
• W2109090088 modified "2023-10-18" @default.
• W2109090088 title "Cyclosporine A for Refractory Interstitial Cystitis/Bladder Pain Syndrome: Experience of 3 Tertiary Centers" @default.
• W2109090088 cites W1551201065 @default.
• W2109090088 cites W1920508857 @default.
• W2109090088 cites W1964393419 @default.
• W2109090088 cites W1967312126 @default.
• W2109090088 cites W1972116180 @default.
• W2109090088 cites W1975063227 @default.
• W2109090088 cites W1976027219 @default.
• W2109090088 cites W2009844792 @default.
• W2109090088 cites W2016941468 @default.
• W2109090088 cites W2021219748 @default.
• W2109090088 cites W2021365806 @default.
• W2109090088 cites W2022363810 @default.
• W2109090088 cites W2030829370 @default.
• W2109090088 cites W2036156711 @default.
• W2109090088 cites W2036536184 @default.
• W2109090088 cites W2059109198 @default.
• W2109090088 cites W2060248732 @default.
• W2109090088 cites W2078545477 @default.
• W2109090088 cites W2090873841 @default.
• W2109090088 cites W2095401957 @default.
• W2109090088 cites W2097247989 @default.
• W2109090088 cites W2102851190 @default.
• W2109090088 cites W2132085141 @default.
• W2109090088 cites W2161807262 @default.
• W2109090088 cites W2164896782 @default.
• W2109090088 cites W2411337338 @default.
• W2109090088 cites W2580183756 @default.
• W2109090088 cites W2794707457 @default.
• W2109090088 cites W4211153129 @default.
• W2109090088 doi "https://doi.org/10.1016/j.juro.2012.06.023" @default.
• W2109090088 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22901569" @default.
• W2109090088 hasPublicationYear "2012" @default.
• W2109090088 type Work @default.
• W2109090088 sameAs 2109090088 @default.
• W2109090088 citedByCount "63" @default.
• W2109090088 countsByYear W21090900882012 @default.
• W2109090088 countsByYear W21090900882013 @default.
• W2109090088 countsByYear W21090900882014 @default.
• W2109090088 countsByYear W21090900882015 @default.
• W2109090088 countsByYear W21090900882016 @default.
• W2109090088 countsByYear W21090900882017 @default.
• W2109090088 countsByYear W21090900882018 @default.
• W2109090088 countsByYear W21090900882019 @default.
• W2109090088 countsByYear W21090900882020 @default.
• W2109090088 countsByYear W21090900882021 @default.
• W2109090088 countsByYear W21090900882022 @default.
• W2109090088 countsByYear W21090900882023 @default.
• W2109090088 crossrefType "journal-article" @default.
• W2109090088 hasAuthorship W2109090088A5033530114 @default.
• W2109090088 hasAuthorship W2109090088A5042149312 @default.
• W2109090088 hasAuthorship W2109090088A5069976268 @default.
• W2109090088 hasConcept C121332964 @default.
• W2109090088 hasConcept C126322002 @default.
• W2109090088 hasConcept C126894567 @default.
• W2109090088 hasConcept C141071460 @default.
• W2109090088 hasConcept C142424586 @default.
• W2109090088 hasConcept C2778508898 @default.
• W2109090088 hasConcept C2909931192 @default.
• W2109090088 hasConcept C2991842025 @default.
• W2109090088 hasConcept C71924100 @default.
• W2109090088 hasConcept C77411442 @default.
• W2109090088 hasConcept C87355193 @default.
• W2109090088 hasConceptScore W2109090088C121332964 @default.
• W2109090088 hasConceptScore W2109090088C126322002 @default.
• W2109090088 hasConceptScore W2109090088C126894567 @default.
• W2109090088 hasConceptScore W2109090088C141071460 @default.
• W2109090088 hasConceptScore W2109090088C142424586 @default.
• W2109090088 hasConceptScore W2109090088C2778508898 @default.
• W2109090088 hasConceptScore W2109090088C2909931192 @default.
• W2109090088 hasConceptScore W2109090088C2991842025 @default.
• W2109090088 hasConceptScore W2109090088C71924100 @default.
• W2109090088 hasConceptScore W2109090088C77411442 @default.
• W2109090088 hasConceptScore W2109090088C87355193 @default.
• W2109090088 hasIssue "4" @default.
• W2109090088 hasLocation W21090900881 @default.
• W2109090088 hasLocation W21090900882 @default.
• W2109090088 hasOpenAccess W2109090088 @default.
• W2109090088 hasPrimaryLocation W21090900881 @default.
• W2109090088 hasRelatedWork W1977436086 @default.
• W2109090088 hasRelatedWork W2035474551 @default.
• W2109090088 hasRelatedWork W2149515360 @default.
• W2109090088 hasRelatedWork W2594781744 @default.
• W2109090088 hasRelatedWork W2625769102 @default.
• W2109090088 hasRelatedWork W2796419937 @default.
• W2109090088 hasRelatedWork W2889709989 @default.
• W2109090088 hasRelatedWork W4236394065 @default.
• W2109090088 hasRelatedWork W4296706835 @default.
• W2109090088 hasRelatedWork W2750290365 @default.
• W2109090088 hasVolume "188" @default.
• W2109090088 isParatext "false" @default.

• next